Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

DeSantis, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. cancer, 136, E359, 10.1002/ijc.29210 Siegel, 2016, Ahmedin Jemal: cancer statistics, 2016, A. Cancer. J. Clin., 66, 271, 10.3322/caac.21349 Barata, 2017, Treatment of renal cell carcinoma: current status and future directions, CA. Cancer. J. Clin., 67, 507, 10.3322/caac.21411 Bedke, 2017, Systemic therapy in metastatic renal cell carcinoma, World. J. Urol., 376, 354 Wang, 2017, Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases, Int. J. Radiat. Oncol. Biol. Phys., 98, 91, 10.1016/j.ijrobp.2017.01.032 Conti, 2017, Oligometastases in genitourinary tumors: recent insights and future molecular diagnostic approach, Eur. Urol. Suppl., 16, 309, 10.1016/j.eursup.2017.09.005 Funayama, 2019, Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy, Technol. Cancer. Res. Treat., 18, 10.1177/1533033818822329 Hoerner-Rieber, 2017, Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma-A multicenter analysis of the German working group “Stereotactic Radiotherapy.”, J. Thorac. Dis., 9, 4512, 10.21037/jtd.2017.10.108 Teh, 2007, The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT), Biomed. Imaging. Interv. J., 3, e6 Svedman, 2006, A prospective phase ii trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma, Acta Oncol. (Madr.), 45, 870, 10.1080/02841860600954875 Wersäll, 2005, Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma, Radiother. Oncol., 77, 88, 10.1016/j.radonc.2005.03.022 Franzese, 2019, Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma, J. Urol., 201, 70, 10.1016/j.juro.2018.08.049 Amini, 2015, Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: is RCC truly radioresistant?, Pract. Radiat. Oncol, 5, e589, 10.1016/j.prro.2015.05.004 Altoos, 2015, Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT), Radiat. Oncol., 10.1186/s13014-015-0528-z Grossman, 2015, Stereotactic body radiation therapy for oligometastatic renal cell carcinoma or melanoma: prognostic factors and outcomes, Int. J. Radiat. Oncol., 10.1016/j.ijrobp.2015.07.1061 Ranck, 2013, Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma, Am. J. Clin. Oncol. Cancer. Clin. Trials., 36, 589, 10.1097/COC.0b013e31825d52b2 Zelefsky, 2012, Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma, Int. J. Radiat. Oncol. Biol. Phys., 82, 1744, 10.1016/j.ijrobp.2011.02.040 Stinauer, 2011, Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control, Radiat. Oncol., 6, 34, 10.1186/1748-717X-6-34 Nguyen, 2010, Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy, Int. J. Radiat. Oncol. Biol. Phys., 76, 1185, 10.1016/j.ijrobp.2009.03.062 Zhang, 2019, Stereotactic ablative radiotherapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer, Radiation Oncol Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer., 45, 228, 10.1016/j.ejca.2008.10.026 National Institute of Health: National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. NIH Publ, 2017. Avaliable at:https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Schemper, 1996, A note on quantifying follow-up in studies of failure time, Control. Clin. Trials., 17, 343, 10.1016/0197-2456(96)00075-X Holm, 1979, A simple sequentially rejective multiple test procedure, Scand. J. Stat, 6, 65 Zaid, 2017, Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis, Journal of Urol, 197, 44, 10.1016/j.juro.2016.07.079 Nobler, 2014, The abscopal effect in malignant lymphoma and its relationship to lymphocyte circulation, Radiology, 93, 410, 10.1148/93.2.410 Formenti, 2013, Combining radiotherapy and cancer immunotherapy: a paradigm shift, J. Natl. Cancer. Inst, 105, 256, 10.1093/jnci/djs629 Trapani, 2019, Effectiveness and safety of “real” concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review, Crit. Rev. Oncol. Hematol., 142, 9, 10.1016/j.critrevonc.2019.07.006 Masini, 2018, NIVES study: a phase ii trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in ii and iii line of patients (pts) with metastatic renal cell carcinoma (mRCC), J. Clin. Oncol., 36, 10.1200/JCO.2018.36.15_suppl.TPS4602